Development of molecular diagnostic assays of clinical utility for gastric and colorectal cancers management
Year: 2022
Type: dissertation
Abstract: The primary need for molecular diagnostic tests to achieve the utmost of performance indices, the rapid development of new targeted therapy, the emergence of new diagnostic histopathology entities requiring differentiation from similar disease entities, and the increasing cancer patient population have necessitated the continuous development of molecular diagnostic assays to meet the challenges and needs of cancer management. In this thesis I present four (4) molecular diagnostics assays which I developed with the aim of improving certain aspects of their performance indices: Squirrel PCR, mHRMA, MSI-HRMA and the MSI-WES assays. The general hypothesis for this study is that the performance indices of a molecular diagnostics test can be improved by altering certain components of the test or by simply using a different test or detection platform. The Squirrel PCR assay was developed with the objective of directly sequencing ultrashort DNA segments by Sanger method. The assay resolves the challenges associated with direct sequencing of sub-100bp DNA segments: poor quality sequencing and inaccurate mutation calling. It uses Squirrel primers to elongate - by PCR - the amplicons of ultrashort DNA molecules, thereby enabling good-quality and accurate sequencing by Sanger method. The preliminary data obtained for the Squirrel PCR assay showed that the assay enabled the achievement of 100% genomic and target sequence qualities by Sanger method compared to the design sequences, and 100% accuracy of mutation detection by Sanger method in standard samples. The Squirrel PCR assay allows the circumvention of the use of next-generation sequencing (NGS), pyrosequencing, and sequencing-by-cloning methods, the current laborious, time-consuming, and expensive methods of sequencing short DNA segments. The Squirrel PCR assay therefore would improve the turnaround time and cost-effectiveness of sequencing short DNA molecules and finds application in small sequencing projects in which the available DNA templates are naturally degenerate or degraded. The consequence of the rapid development of targeted therapy for cancer management is that more genetic targets need to be tested in each patient’s tumour for evidence of predictive variants. For most molecular diagnostics laboratories where limited testing is the routine it is impractical to acquire expensive high throughput mutation detection platforms, and small improvements in performance (in this case, the speed of testing) of existing assays may be all that is required. The mHRMA assay is a high-resolution melting analysis-based assay which combines the exquisite sensitivity of high-resolution melting analysis (HRMA) and the developed capacity to multiplex targets in the HRMA platform, to achieve rapid detection of mutations in colorectal cancer (CRC). The mHRMA assay utilises differential tagging of amplicons with GC-tails – by using GC-tagged primers - to achieve adequate separation of the melting temperatures of amplicons and enable robust duplexing and triplexing of targets. The capacity for multiplexing in the HRMA detection platform makes mHRMA a faster, more cost-effective, and less laborious mutation detection assay than the conventional, single target HRMA. In this development, preliminary data showed that the mHRMA assay can achieve a perfect concordance and 100% sensitivity, specificity, and accuracy compared with the single target HRMA tests. Microsatellite instability (MSI) testing recently achieved additional relevance in cancer management because of its newly discovered predictive value in the use of the highly effective immune checkpoint inhibitors. The implication of its new relevance means that more cancer patients would undergo MSI testing to determine their suitability for immunotherapy. Thus, the need for a faster, less laborious, and probably more cost-effective MSI testing method. The MSI-HRMA assay tests MSI in CRC using a combination of established (BAT-25, BAT-26, MONO-27) and novel (TYMS-26, BCAT-25, MYB, ANGEL2, TP53 (BAT34CA), FBXO46 and TCF4) microsatellite markers in the HRMA detection platform. The selected panels of the MSI-HRMA markers achieved sensitivities, specificities, and accuracies of 91.3-100%, 100% and 100%, respectively, compared to the gold standards. However, because of its detection platform MSI-HRMA is easier, faster, and more cost-effective to set up and run than either capillary electrophoresis (CE) or immunohistochemistry (IHC). Also, as shown by the mHRMA assay, the MSI-HRMA can be multiplexed to further reduce the labour, cost and turnaround time associated with MSI testing. One advantage of using NGS for mutation detection is that huge numbers of variants, including clinically relevant single nucleotide variants (SNVs) as well as microsatellite-based indels, can be tested in single NGS experiments, thereby obviating the necessity for separate experiments for SNV detection and for MSI testing. The MSI-WES was designed as a simple strategy for testing MSI in gastric cancer (GCa) using level 2 whole exome sequencing (WES) data as recorded in variant call format (vcf) files. MSI-WES simply counts the insertions and deletions (indels) occurring within microsatellite contexts and uses the count-based indices as MSI scores. Based on a well-defined threshold of MSI scores MSI-WES robustly classified each GCa case into MSI or MSS. MSI-WES achieved a near-perfect concordance with the PCR-based MSI test, and sensitivity, specificity, and accuracy of 100%, 99.03% and 99.22%, respectively. The attraction for MSI-WES is its simplicity of MSI-testing strategy devoid of complex statistical permutations. Furthermore, MSI testing is performed on the same processed vcf files from which other clinically relevant mutation types are extracted. Each of the four assays were validated to variable extents as discussed in the thesis.
Author: EBILI, HENRY OKUCHUKWU
Institution: University of Nottingham
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7218273505
